Welcome to the registration website for

ASH 2020 Meeting Highlights
in Myeloproliferative Neoplasms

Join us for this educational event and earn
1.0 LIVE CME/CPE/CNE credit hour.

Did you miss ASH this year or want to hear additional reports you may have missed from oral or poster presentations?

Register Now

Join us for the opportunity to interact live with Dr. Mesa, Dr. Gerds,and Dr. Mascarenhas as they review selected abstracts covered in myeloproliferative neoplasms

Faculty

Dr. Ruben Mesa Dr. Aaron Gerds Dr. John Mascarenhas
Ruben Mesa, MD
Director
Mays Cancer Center
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas
Aaron Gerds, MD
Associate Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio
John Mascarenhas, MD
Associate Professor of Medicine
Tisch Cancer Institute, Division of Hematology/Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

During the live presentation, you will have the opportunity to submit your questions directly to the faculty and hear up-to-the-minute discussion and expert analysis on ongoing trials impacting treatment today and in the future.

Agenda

10 minutes Current Landscape and Unmet Needs
35 minutes Expert Analysis and Discussion of Select Highlights
Topics will include analysis of:
  • A Phase 2 Study of the LSD1 Inhibitor IMG7289 (Bomedemstat)
  • An Update of the IMbark Phase 2 Study of Imetelstat for R/R Myelofibrosis
  • New Therapies and JAKi-based Combinations for Myelofibrosis Including the Addition of Navitoclax to Ruxolitinib, and Update of the MANIFEST Phase 2 Study; BET Inhibitor in Combination with Ruxolitinib
  • Overall Survival and Sustained Efficacy Outcomes for Momelotinib
  • Updated Analysis of Key Trials in PV Including Results of the International Phase 2 Study of Idasanutlin in Patients with HU-resistant PV; 5-year Results in Long-term Use of Ropeginterferon Alpha-2b and Phase 2 Results of PTG-300
15 minutes Audience Q/A with Panel



Target Audience
This activity is designed for multidisciplinary healthcare providers including physicians, nurses, pharmacists, and other allied healthcare professionals who provide medical care to patients with myeloproliferative neoplasms (MPN).

Learning Objectives
Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with myelofibrosis (MF), polycythemia vera (PV) or essential thrombocythemia (ET)
  • Outline clinical trials and recent advances in the diagnosis, treatment, and management of MF, PV, or ET
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in MPN

Accreditation

MediCom Worldwide, Inc. CME Credit
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-008-L01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc. Nursing Credit
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-008-135

Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures
Dr. Ruben Mesa has received honoraria as a consultant from Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Geron, Novartis AG, Samus Therapeutics, Inc., and Sierra Oncology, Inc. He has received grant support related to research activities from AbbVie Inc., Bristol-Myers Squibb, CTI BioPharma Corp., and Incyte Corporation.

Dr. Aaron Gerds has received honoraria related to formal advisory activities from Constellation Pharmaceuticals, CTI BioPharma Corp., Galecto Biotech, PharmaEssentia Corporation, and Promedior, Inc.

Dr. John Mascarenhas has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation – A Bristol-Myers Squibb Company, Constellation Pharmaceuticals, F. Hoffmann-La Roche Ltd, Geron, Incyte Corporation, and PharmaEssentia Corporation. He has received grant support related to research activities from AROG Pharmaceuticals, Inc., CTI BioPharma Corp., F. Hoffmann-La Roche, Forbius, Incyte, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Merus, Novartis AG, and PharmaEssentia.

Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Instructions for Participation and Credit
There are no fees for participating in this activity.

In order to receive credit, all participants must complete the self-assessment post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.

Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.

CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x110 or cjacobus@medicaled.com.

Provided by
MediCom Worldwide, Inc.

Supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.